Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Mol Neurodegener ; 16(1): 17, 2021 03 19.
Artículo en Inglés | MEDLINE | ID: mdl-33741046

RESUMEN

The most common mutation in the Leucine-rich repeat kinase 2 gene (LRRK2), G2019S, causes familial Parkinson's Disease (PD) and renders the encoded protein kinase hyperactive. While targeting LRRK2 activity is currently being tested in clinical trials as a therapeutic avenue for PD, to date, the molecular effects of chronic LRRK2 inhibition have not yet been examined in vivo. We evaluated the utility of newly available phospho-antibodies for Rab substrates and LRRK2 autophosphorylation to examine the pharmacodynamic response to treatment with the potent and specific LRRK2 inhibitor, MLi-2, in brain and peripheral tissue in G2019S LRRK2 knock-in mice. We report higher sensitivity of LRRK2 autophosphorylation to MLi-2 treatment and slower recovery in washout conditions compared to Rab GTPases phosphorylation, and we identify pS106 Rab12 as a robust readout of downstream LRRK2 activity across tissues. The downstream effects of long-term chronic LRRK2 inhibition in vivo were evaluated in G2019S LRRK2 knock-in mice by phospho- and total proteomic analyses following an in-diet administration of MLi-2 for 10 weeks. We observed significant alterations in endolysosomal and trafficking pathways in the kidney that were sensitive to MLi-2 treatment and were validated biochemically. Furthermore, a subtle but distinct biochemical signature affecting mitochondrial proteins was observed in brain tissue in the same animals that, again, was reverted by kinase inhibition. Proteomic analysis in the lung did not detect any major pathway of dysregulation that would be indicative of pulmonary impairment. This is the first study to examine the molecular underpinnings of chronic LRRK2 inhibition in a preclinical in vivo PD model and highlights cellular processes that may be influenced by therapeutic strategies aimed at restoring LRRK2 physiological activity in PD patients.


Asunto(s)
Endosomas/efectos de los fármacos , Indazoles/farmacología , Proteína 2 Quinasa Serina-Treonina Rica en Repeticiones de Leucina/antagonistas & inhibidores , Lisosomas/efectos de los fármacos , Enfermedad de Parkinson/enzimología , Inhibidores de Proteínas Quinasas/farmacología , Pirimidinas/farmacología , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Evaluación Preclínica de Medicamentos , Endosomas/fisiología , Mutación con Ganancia de Función , Técnicas de Sustitución del Gen , Humanos , Riñón/efectos de los fármacos , Riñón/metabolismo , Proteína 2 Quinasa Serina-Treonina Rica en Repeticiones de Leucina/genética , Proteína 2 Quinasa Serina-Treonina Rica en Repeticiones de Leucina/metabolismo , Pulmón/efectos de los fármacos , Pulmón/metabolismo , Lisosomas/fisiología , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Proteínas Mitocondriales/metabolismo , Especificidad de Órganos , Fosforilación/efectos de los fármacos , Mutación Puntual , Procesamiento Proteico-Postraduccional/efectos de los fármacos , Proteoma/efectos de los fármacos , Distribución Aleatoria , Proteínas de Unión al GTP rab/metabolismo
2.
Am J Chin Med ; 48(8): 1915-1940, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33308096

RESUMEN

Autophagy is an important tightly controlled cellular process that regulates cellular homeostasis and is involved in deciding cell fate such as cell survival and death. The role of autophagy in many intracellular signaling pathways explains its interaction with other different types of cell death, including apoptosis and immunogenic cell death (ICD). The reports showed the complex and intriguing relationship existing between autophagy and immune system signaling pathways. However, the role of autophagy in ICD remains to be clearly elucidated. In this study, we demonstrated that Brucine, a clinically-used small molecule in traditional Chinese medicine, elicited autophagy inhibition. Brucine also triggered cell stress and induced features of ICD, including calreticulin (CRT) exposure and high-mobility group box 1 (HMGB1) release in MDA-MB-231 and CT26 cancer cells. Brucine impaired autolysosomal degradation and exerted a feedback regulation of ERK1/2-mTOR-p70S6K signaling cascade. Brucine-elicited ICD was confirmed by the rejection of CT26 tumor cells, implanted in the mice after vaccination with Brucine-treated CT26 cells. The impaired autophagy contributed to Brucine-induced ICD, as knock-down of Atg5 significantly reduced Brucine-elicited CRT exposure and HMGB1 release. Our results revealed Brucine as a novel autophagy regulator, ICD inducer and hitherto undocumented role of autophagy in ICD. Thus, these results imply the importance of Brucine in cancer immunotherapy. Therefore, Brucine may be used as an ICD inducer and improve its application in cancer treatment with minimized toxicity.


Asunto(s)
Autofagia/efectos de los fármacos , Muerte Celular/genética , Muerte Celular/inmunología , Medicamentos Herbarios Chinos , Lisosomas/efectos de los fármacos , Estricnina/análogos & derivados , Animales , Autofagia/fisiología , Proteína 5 Relacionada con la Autofagia/genética , Calreticulina , Línea Celular Tumoral , Técnicas de Silenciamiento del Gen , Proteína HMGB1/metabolismo , Humanos , Inmunoterapia , Lisosomas/fisiología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Ratones , Neoplasias/tratamiento farmacológico , Fitoterapia , Estricnina/farmacología , Estricnina/uso terapéutico
3.
Neuroreport ; 31(10): 697-701, 2020 07 10.
Artículo en Inglés | MEDLINE | ID: mdl-32427802

RESUMEN

Besides degradation, lysosomes can also carry molecules for secretion out of the cell, such as ATP and cytokines, during unconventional secretion. Phosphatidylinositols and their metabolizing enzymes play important roles in the sorting and trafficking of lysosomal materials through the trans-Golgi network. The present study reveals a new function of phosphatidylinositol kinase-III alpha in the 'kiss-and-run' fusion of lysosomes at the plasma membrane to release ATP from microglia.


Asunto(s)
Exocitosis , Lisosomas/fisiología , Microglía/fisiología , Fosfatidilinositol 3-Quinasa/fisiología , Adenosina Trifosfato/metabolismo , Animales , Células Cultivadas , Ratones Endogámicos C57BL
4.
J Mycol Med ; 30(2): 100965, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32307255

RESUMEN

Cryptococcosis is an opportunistic systemic mycosis whose treatment is limited to three drugs. In this work, we evaluated the antifungal activity of a hexane extract (HE) from Spondias tuberosa leaves against Cryptococcus neoformans and Cryptococcus gattii. Minimal inhibitory concentrations (MIC) were determined, and putative mechanisms were evaluated by flow cytometry. In addition, an in vivo infection assay was performed using Tenebrio molitor larvae. Treatment with HE inhibited the growth of standard and clinical isolates of C. neoformans and C. gattii (MICs ranging from 0.78 to 3.12mg/mL), significantly (P<0.05) increased mitochondrial superoxide anion levels, and induced mitochondrial membrane depolarization, loss of lysosomal membrane integrity, and phosphatidylserine externalization. The mean survival time of C. gattii-infected T. molitor larvae significantly (P<0.05) increased from 1.225 days in control to 3.067 and 3.882 days in HE-treated groups (78 and 156mg/kg, respectively). In conclusion, HE showed anticryptococcal activity, induced mitochondrial and lysosomal damage in yeast cells, and exhibited anti-infective action against C. gattii in T. molitor larvae.


Asunto(s)
Anacardiaceae/química , Antifúngicos/aislamiento & purificación , Antifúngicos/farmacología , Criptococosis/tratamiento farmacológico , Hexanos/química , Animales , Antifúngicos/efectos adversos , Antifúngicos/uso terapéutico , Criptococosis/patología , Cryptococcus gattii/citología , Cryptococcus gattii/efectos de los fármacos , Cryptococcus gattii/ultraestructura , Cryptococcus neoformans/citología , Cryptococcus neoformans/efectos de los fármacos , Cryptococcus neoformans/ultraestructura , Hexanos/farmacología , Humanos , Larva/efectos de los fármacos , Lisosomas/efectos de los fármacos , Lisosomas/fisiología , Pruebas de Sensibilidad Microbiana , Mitocondrias/efectos de los fármacos , Mitocondrias/fisiología , Fitoterapia , Extractos Vegetales/química , Tenebrio/efectos de los fármacos , Tenebrio/crecimiento & desarrollo , Pruebas de Toxicidad
5.
Mol Cell ; 77(3): 645-655.e7, 2020 02 06.
Artículo en Inglés | MEDLINE | ID: mdl-31983508

RESUMEN

The lysosome is an acidic multi-functional organelle with roles in macromolecular digestion, nutrient sensing, and signaling. However, why cells require acidic lysosomes to proliferate and which nutrients become limiting under lysosomal dysfunction are unclear. To address this, we performed CRISPR-Cas9-based genetic screens and identified cholesterol biosynthesis and iron uptake as essential metabolic pathways when lysosomal pH is altered. While cholesterol synthesis is only necessary, iron is both necessary and sufficient for cell proliferation under lysosomal dysfunction. Remarkably, iron supplementation restores cell proliferation under both pharmacologic and genetic-mediated lysosomal dysfunction. The rescue was independent of metabolic or signaling changes classically associated with increased lysosomal pH, uncoupling lysosomal function from cell proliferation. Finally, our experiments revealed that lysosomal dysfunction dramatically alters mitochondrial metabolism and hypoxia inducible factor (HIF) signaling due to iron depletion. Altogether, these findings identify iron homeostasis as the key function of lysosomal acidity for cell proliferation.


Asunto(s)
Proliferación Celular/fisiología , Hierro/metabolismo , Lisosomas/metabolismo , Colesterol/biosíntesis , Colesterol/metabolismo , Células HEK293 , Células HeLa , Homeostasis , Humanos , Concentración de Iones de Hidrógeno , Células Jurkat , Lisosomas/fisiología , Mitocondrias/metabolismo , Transducción de Señal/genética
6.
SLAS Discov ; 24(3): 295-303, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30616450

RESUMEN

Tay-Sachs disease is an inherited lysosomal storage disease resulting from mutations in the lysosomal enzyme, ß-hexosaminidase A, and leads to excessive accumulation of GM2 ganglioside. Tay-Sachs patients with the infantile form do not live beyond 2-4 years of age due to rapid, progressive neurodegeneration. Enzyme replacement therapy is not a therapeutic option due to its inability to cross the blood-brain barrier. As an alternative, small molecules identified from high-throughput screening could provide leads suitable for chemical optimization to target the central nervous system. We developed a new high-throughput phenotypic assay utilizing infantile Tay-Sachs patient cells based on disrupted lysosomal calcium signaling as a monitor of diseased phenotype. The assay was validated in a pilot screen on a collection of Food and Drug Administration-approved drugs to identify compounds that could reverse or attenuate the disease. Pyrimethamine, a known pharmacological chaperone of ß-hexosaminidase A, was identified from the primary screen. The mechanism of action of pyrimethamine in reversing the defective lysosomal phenotype was by improving autophagy. This new high-throughput screening assay in patient cells will enable the screening of larger chemical compound collections. Importantly, this approach could lead to identification of new molecular targets previously unknown to impact the disease and accelerate the discovery of new treatments for Tay-Sachs disease.


Asunto(s)
Ensayos Analíticos de Alto Rendimiento/métodos , Lisosomas/fisiología , Bibliotecas de Moléculas Pequeñas/análisis , Enfermedad de Tay-Sachs/fisiopatología , Autofagia , Señalización del Calcio/efectos de los fármacos , Línea Celular , Evaluación Preclínica de Medicamentos , Humanos , Lisosomas/metabolismo , Proyectos Piloto , Prueba de Estudio Conceptual , Bibliotecas de Moléculas Pequeñas/uso terapéutico , Enfermedad de Tay-Sachs/tratamiento farmacológico , Enfermedad de Tay-Sachs/metabolismo
7.
J Toxicol Environ Health A ; 81(16): 792-804, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30001190

RESUMEN

Pouteria ramiflora (Mart.) Radlk., popularly known as curriola, is commonly used in Brazil as medicinal plant to treat worm infections, dysentery, pain, inflammation, hyperlipidemia, and obesity. At present the safety of this extract when used therapeutically in human remains to be determined. Thus, the aim of this study was to examine cytotoxicity, antiproliferative, and antimutagenic actions of this extract. The hydroalcoholic extract from P. ramiflora leaves consisted of flavonoids identified and quantified as myricetin-3-O-ß-D-galactopyranoside (13.55 mg/g) and myricetin-3-O-α-L-rhamnopyranoside (9.61 mg/g). The extract exhibited cytotoxicity at concentrations higher than 1.5 µg/ml in human hepatocarcinoma (HepG2)and 2.5 µg/ml in non-tumoral primary gastric (GAS) cells using the MTT assay, and at concentrations higher than 3 µg/ml in HepG2 and 3.5 µg/ml in GAS cells by the neutral red assay. The extract did not show antiproliferative effect as evidenced by the nuclear division index (NDI). However, in the presence of benzo[a]pyrene (BaP) (positive control), an enhanced cytostatic effect in the NDI and flow cytometry was noted. It is of interest that when the extract was co-incubated with BaP a significant decrease in DNA damage was observed indicating an antimutagenic action. This protective effect might be attributed to myricetin and gallic acid found in P. ramiflora extract. The low cytotoxicity action and protective effect observed in the present study encourage further studies regarding other biological effects of P. ramiflora, as well as its potential use as a chemopreventive agent.


Asunto(s)
Membrana Celular/efectos de los fármacos , Flavonoides/farmacología , Lisosomas/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Extractos Vegetales/farmacología , Pouteria/química , Brasil , Línea Celular , Membrana Celular/fisiología , Proliferación Celular/efectos de los fármacos , Cromatografía Líquida de Alta Presión , Células Hep G2 , Humanos , Lisosomas/fisiología , Mitocondrias/fisiología , Pruebas de Mutagenicidad , Oxidantes/metabolismo , Hojas de la Planta/química , Sustancias Protectoras/farmacología
8.
World J Gastroenterol ; 23(29): 5333-5344, 2017 Aug 07.
Artículo en Inglés | MEDLINE | ID: mdl-28839433

RESUMEN

AIM: To investigate the capability of salvianolic acid B (Sal B) to protect hepatocytes from hydrogen peroxide (H2O2)/carbon tetrachloride (CCl4)-induced lysosomal membrane permeabilization. METHODS: Cell Counting Kit-8 assay was used to measure cell viability. Apoptosis and death were assayed through flow cytometry. BrdU incorporation was used to detect cell proliferation. Serum alanine aminotransferase activity and liver malondialdehyde (MDA) content were measured. Liver histopathological changes were evaluated using hematoxylin-eosin staining. Lysosomal membrane permeability was detected with LysoTracker Green-labeled probes and acridine orange staining. The levels of protein carbonyl content (PCC), cathepsins (Cat)B/D, and lysosome-associated membrane protein 1 (LAMP1) were evaluated through western blotting. Cytosol CatB activity analysis was performed with chemiluminescence detection. The mRNA level of LAMP1 was evaluated through quantitative real-time polymerase chain reaction. RESULTS: Results indicated that H2O2 induced cell injury/death. Sal B attenuated H2O2-induced cell apoptosis and death, restored the inhibition of proliferation, decreased the amount of PCC, and stabilized the lysosome membrane by increasing the LAMP1 protein level and antagonizing CatB/D leakage into the cytosol. CCl4 also triggered hepatocyte death. Furthermore, Sal B effectively rescued hepatocytes by increasing LAMP1 expression and by reducing lysosomal enzyme translocation to the cytosol. CONCLUSION: Sal B protected mouse embryonic hepatocytes from H2O2/CCl4-induced injury/death by stabilizing the lysosomal membrane.


Asunto(s)
Benzofuranos/farmacología , Permeabilidad de la Membrana Celular/efectos de los fármacos , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Medicamentos Herbarios Chinos/farmacología , Membranas Intracelulares/efectos de los fármacos , Lisosomas/efectos de los fármacos , Alanina Transaminasa/sangre , Animales , Apoptosis/efectos de los fármacos , Benzofuranos/uso terapéutico , Western Blotting , Tetracloruro de Carbono/toxicidad , Catepsina A/metabolismo , Catepsina B/metabolismo , Línea Celular , Supervivencia Celular/efectos de los fármacos , Enfermedad Hepática Inducida por Sustancias y Drogas/sangre , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Citosol/metabolismo , Medicamentos Herbarios Chinos/uso terapéutico , Citometría de Flujo , Hepatocitos , Humanos , Peróxido de Hidrógeno/toxicidad , Hígado/citología , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Proteínas de Membrana de los Lisosomas/metabolismo , Lisosomas/fisiología , Masculino , Ratones , Ratones Endogámicos BALB C , Carbonilación Proteica/efectos de los fármacos , Reacción en Cadena en Tiempo Real de la Polimerasa , Salvia miltiorrhiza/química , Transducción de Señal
9.
Cancer Lett ; 366(1): 19-31, 2015 Sep 28.
Artículo en Inglés | MEDLINE | ID: mdl-26118776

RESUMEN

In this study, the anti-cancer effect of Icariside II (IS), a natural plant flavonoid, against hepatoblastoma cells and the underlying mechanisms were investigated. The in vitro and in vivo studies show that IS decreased the viability of human hepatoblastoma HepG2 cells in a concentration- and time-dependent manner and inhibited tumor growth in mice transplanted with H22 liver carcinomas. IS impaired mitochondria and lysosomes as evidenced by signs of induced mitochondrial and lysosomal membrane permeabilization, resulting in caspase activation and apoptosis. SQSTM1 up-regulation and autophagic flux measurements demonstrated that IS exposure also impaired autophagosome degradation which resulted in autophagosome accumulation, which plays a pro-survival role as the genetic knockdown of LC3B further sensitized the IS-treated cells. Electron microscopy images showed that autophagosome engulfs IS-impaired mitochondria and lysosomes, thus blocking cytotoxicity induced by further leakage of the hydrolases from lysosomes and pro-apoptosis members from mitochondria. In conclusion, these data suggest that IS plays multiple roles as a promising chemotherapeutic agent that induces cell apoptosis involving both mitochondrial and lysosomal damage.


Asunto(s)
Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Autofagia , Medicamentos Herbarios Chinos/farmacología , Flavonoides/farmacología , Hepatoblastoma/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Lisosomas/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Animales , Proliferación Celular/efectos de los fármacos , Hepatoblastoma/patología , Humanos , Neoplasias Hepáticas/patología , Lisosomas/fisiología , Masculino , Ratones , Ratones Endogámicos ICR , Mitocondrias/fisiología
11.
Blood ; 125(10): 1623-32, 2015 Mar 05.
Artículo en Inglés | MEDLINE | ID: mdl-25477496

RESUMEN

Hermansky-Pudlak syndrome (HPS) is characterized by oculocutaneous albinism, bleeding diathesis, and other variable symptoms. The bleeding diathesis has been attributed to δ storage pool deficiency, reflecting the malformation of platelet dense granules. Here, we analyzed agonist-stimulated secretion from other storage granules in platelets from mouse HPS models that lack adaptor protein (AP)-3 or biogenesis of lysosome-related organelles complex (BLOC)-3 or BLOC-1. We show that α granule secretion elicited by low agonist doses is impaired in all 3 HPS models. High agonist doses or supplemental adenosine 5'-diphosphate (ADP) restored normal α granule secretion, suggesting that the impairment is secondary to absent dense granule content release. Intravital microscopy following laser-induced vascular injury showed that defective hemostatic thrombus formation in HPS mice largely reflected reduced total platelet accumulation and affirmed a reduced area of α granule secretion. Agonist-induced lysosome secretion ex vivo was also impaired in all 3 HPS models but was incompletely rescued by high agonist doses or excess ADP. Our results imply that (1) AP-3, BLOC-1, and BLOC-3 facilitate protein sorting to lysosomes to support ultimate secretion; (2) impaired secretion of α granules in HPS, and to some degree of lysosomes, is secondary to impaired dense granule secretion; and (3) diminished α granule and lysosome secretion might contribute to pathology in HPS.


Asunto(s)
Plaquetas/fisiología , Síndrome de Hermanski-Pudlak/sangre , Complejo 3 de Proteína Adaptadora/deficiencia , Complejo 3 de Proteína Adaptadora/genética , Complejo 3 de Proteína Adaptadora/fisiología , Adenosina Difosfato/farmacología , Animales , Proteínas Portadoras/genética , Proteínas Portadoras/fisiología , Degranulación de la Célula/fisiología , Modelos Animales de Enfermedad , Factores de Intercambio de Guanina Nucleótido , Síndrome de Hermanski-Pudlak/etiología , Síndrome de Hermanski-Pudlak/genética , Humanos , Péptidos y Proteínas de Señalización Intracelular , Lectinas/deficiencia , Lectinas/genética , Lectinas/fisiología , Lisosomas/fisiología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Selectina-P/sangre , Proteínas SNARE/sangre , Vesículas Secretoras/fisiología , Trombina/farmacología , Trombosis/sangre , Trombosis/etiología , Proteínas de Transporte Vesicular/deficiencia , Proteínas de Transporte Vesicular/genética , Proteínas de Transporte Vesicular/fisiología
12.
Redox Biol ; 2: 82-90, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24494187

RESUMEN

Oxidative stress including DNA damage, increased lipid and protein oxidation, are important features of aging and neurodegeneration suggesting that endogenous antioxidant protective pathways are inadequate or overwhelmed. Importantly, oxidative protein damage contributes to age-dependent accumulation of dysfunctional mitochondria or protein aggregates. In addition, environmental toxins such as rotenone and paraquat, which are risk factors for the pathogenesis of neurodegenerative diseases, also promote protein oxidation. The obvious approach of supplementing the primary antioxidant systems designed to suppress the initiation of oxidative stress has been tested in animal models and positive results were obtained. However, these findings have not been effectively translated to treating human patients, and clinical trials for antioxidant therapies using radical scavenging molecules such as α-tocopherol, ascorbate and coenzyme Q have met with limited success, highlighting several limitations to this approach. These could include: (1) radical scavenging antioxidants cannot reverse established damage to proteins and organelles; (2) radical scavenging antioxidants are oxidant specific, and can only be effective if the specific mechanism for neurodegeneration involves the reactive species to which they are targeted and (3) since reactive species play an important role in physiological signaling, suppression of endogenous oxidants maybe deleterious. Therefore, alternative approaches that can circumvent these limitations are needed. While not previously considered an antioxidant system we propose that the autophagy-lysosomal activities, may serve this essential function in neurodegenerative diseases by removing damaged or dysfunctional proteins and organelles.


Asunto(s)
Antioxidantes/fisiología , Autofagia , Lisosomas/fisiología , Enfermedades Neurodegenerativas/metabolismo , Envejecimiento/metabolismo , Animales , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Antiparkinsonianos/farmacología , Antiparkinsonianos/uso terapéutico , Encéfalo/metabolismo , Ensayos Clínicos como Asunto , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Humanos , Peroxidación de Lípido , Proteínas del Tejido Nervioso/metabolismo , Enfermedades Neurodegenerativas/tratamiento farmacológico , Enfermedades Neurodegenerativas/patología , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/uso terapéutico , Oxidación-Reducción , Estrés Oxidativo , Oxidorreductasas/fisiología , Trastornos Parkinsonianos/tratamiento farmacológico , Trastornos Parkinsonianos/metabolismo , Trastornos Parkinsonianos/patología , Ácido Peroxinitroso/metabolismo
13.
J Biol Regul Homeost Agents ; 27(2): 365-75, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23830387

RESUMEN

Nowadays, manufactured nano-particles of aluminum oxide (nano-alumina) have been widely used in many fields with the rapidly developed nano-technology, but their basic toxic data are scarce. It is believed that the smaller nano-particles are able to easily cross the bio-membrane and quickly reach cellular compartments rather than micro-size particles, thus showing more toxic effects. The aim of this study was to compare the toxicity of nano- and micro- particles of alumina for detecting particle size related toxicity, and to compare the toxicity of nano-alumina and nano-carbon with the same particle size for determining chemical composition related toxicity. The present study revealed that nano-particles of alumina were much toxic than micro-alumina particles, indicating a particle size related toxicity; and were much more toxic than nano-carbon particles as well, manifesting a chemical related toxicity. The mechanism might be concerned with the involvement of the lysosomes. In conclusion, toxicity of nano-alumina is a combination of the toxic effects of its particle size and chemical composition.


Asunto(s)
Óxido de Aluminio/toxicidad , Lisosomas/fisiología , Nanopartículas del Metal/toxicidad , Óxido de Aluminio/análisis , Animales , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Tamaño de la Partícula , Ratas , Ratas Sprague-Dawley
14.
Alzheimers Dement ; 9(4): 452-458.e1, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23809366

RESUMEN

For decades, researchers have focused primarily on a pathway initiated by amyloid beta aggregation, amyloid deposition, and accumulation in the brain as the key mechanism underlying the disease and the most important treatment target. However, evidence increasingly suggests that amyloid is deposited early during the course of disease, even prior to the onset of clinical symptoms. Thus, targeting amyloid in patients with mild to moderate Alzheimer's disease (AD), as past failed clinical trials have done, may be insufficient to halt further disease progression. Scientists are investigating other molecular and cellular pathways and processes that contribute to AD pathogenesis. Thus, the Alzheimer's Association's Research Roundtable convened a meeting in April 2012 to move beyond amyloid and explore AD as a complex multifactorial disease, with the goal of using a more inclusive perspective to identify novel treatment strategies.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Terapia Molecular Dirigida , Nootrópicos/uso terapéutico , Envejecimiento , Enfermedad de Alzheimer/diagnóstico , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/fisiopatología , Péptidos beta-Amiloides/metabolismo , Animales , Autofagia/efectos de los fármacos , Biomarcadores , Encéfalo/metabolismo , Ciclo Celular/efectos de los fármacos , Conducta Cooperativa , Diabetes Mellitus Tipo 2/complicaciones , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Humanos , Inflamación , Resistencia a la Insulina , Lisosomas/efectos de los fármacos , Lisosomas/fisiología , Ratones , Ratones Transgénicos , Mitocondrias/efectos de los fármacos , Mitocondrias/patología , Modelos Neurológicos , Neuroimagen , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neuronas/patología , Nootrópicos/farmacología , Asociación entre el Sector Público-Privado , Asignación de Recursos , Proteínas tau/efectos de los fármacos , Proteínas tau/fisiología
15.
Int J Hyperthermia ; 27(5): 409-14, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21756038

RESUMEN

PURPOSE: We aim to explore the role of macroautophagy in cellular responses to hyperthermia. Protein damage incurred during hyperthermia can either lead to cell death or may be repaired by polypeptide quality control pathways including: (1) the deterrence of protein unfolding by molecular chaperones and (2) proteolysis of the denatured proteins within the proteasome. A third pathway of protein quality control is triggered by formation of protein aggregates in the heat shocked cell. This is the macroautophagy pathway in which protein aggregates are transported to specialised organelles called autolysosomes capable of degrading the aggregates. The consequences for cell viability of triggering this pathway are complex and may involve cell death, although under many circumstances, including exposure of cells to hyperthermia, autophagy leads to enhanced cell survival. We have discussed mechanisms by which cells detect protein aggregates and recruit them into the macroautophagy pathway as well as the potential role of inhibiting this process in hyperthermia. CONCLUSIONS: Directed macroautophagy, with its key role in protein quality control, seems an attractive target for a therapy such as hyperthermia that functions principally through denaturing the proteome. However, much work is needed to decode the mechanisms of thermal stress-mediated macroautophagy and their role in survival/death of cancer cells before recommendations can be made on targeting this pathway in combination with hyperthermia.


Asunto(s)
Autofagia/fisiología , Fiebre/metabolismo , Hipertermia Inducida , Apoptosis/fisiología , Proteínas Reguladoras de la Apoptosis/fisiología , Beclina-1 , Supervivencia Celular/fisiología , Proteínas de Choque Térmico/biosíntesis , Humanos , Lisosomas/fisiología , Quinasa 1 de Quinasa de Quinasa MAP/metabolismo , Proteínas de la Membrana/fisiología , Chaperonas Moleculares/fisiología , Neoplasias/terapia , Complejo de la Endopetidasa Proteasomal/metabolismo , Desnaturalización Proteica , Desplegamiento Proteico , Serina-Treonina Quinasas TOR/antagonistas & inhibidores
16.
J Environ Monit ; 13(4): 901-14, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21290064

RESUMEN

In order to assess the long-term lysosomal responses to the Prestige oil spill (POS), mussels, Mytilus galloprovincialis, were collected in 22 localities from Galicia and the Bay of Biscay (North Iberian peninsula) in July, and September 2003, April, July, and October 2004-2005 and April 2006. Lysosomal membrane stability (labilisation period, LP) and lysosomal structural changes (lysosomal volume density, Vv(L) and lysosomal surface-to-volume ratio, S/V(L)) were measured as general stress biomarkers. The most remarkable long-term effects after the POS were drastic changes in lysosomal size (lysosomal enlargement) and membrane stability (extremely low LP values) up to April-04. Later on, a recovery trend was envisaged all along the studied area after July-04, albeit membrane stability continued to be below 20 min throughout the studied period up to April-06, which indicates a "distress-to-moderate-stress" condition. Lysosomal Response Index (LRI) revealed that environmental stress was more marked in Galicia than in the Bay of Biscay, mainly in the first sampling year, although a "moderate-to-high-stress" condition persisted until July-05. Overall, although lysosomal size returned to reference values, membrane stability was not fully recovered indicating a stress situation throughout the studied period.


Asunto(s)
Accidentes , Biomarcadores/metabolismo , Monitoreo del Ambiente/métodos , Tracto Gastrointestinal/metabolismo , Lisosomas/fisiología , Petróleo , Contaminantes Químicos del Agua/toxicidad , Animales , Secuencia de Bases , Bivalvos , Cartilla de ADN , España
17.
Biochem J ; 410(1): 81-92, 2008 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-17939778

RESUMEN

Alterations in sulfatide metabolism, trafficking and homoeostasis are present at the earliest clinically recognizable stages of Alzheimer's disease and are associated with metachromatic leukodystrophy. However, the role of sulfatide in these disease states remains unknown. In the present study, we investigated the sequelae of NB (neuroblastoma) cells upon sulfatide supplementation and the biochemical mechanisms contributing to the sulfatide-induced changes. By using shotgun lipidomics, we showed dramatic accumulations of sulfatide, ceramide and sphingosine in NB cells in a time- and dose-dependent manner. Further studies utilizing subcellular fractionation and shotgun lipidomics analyses demonstrated that most of the increased ceramide content was generated in the endosomal compartment, whereas sulfatides predominantly accumulated in lysosomes. In addition, we determined that the sulfatide-mediated increase in endosomal ceramide content mainly resulted from beta-galactosidase activity, which directly hydrolyses sulfatide to ceramide without a prior desulfation step. Substantial cell apoptosis occurred in parallel with the accumulation of sulfatides and ceramides, as revealed by mitochondrial membrane depolarization, by phosphatidylserine translocation and by the TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling) assay. These findings were also demonstrated with primary neuron cultures. Collectively, our results demonstrate that abnormal sulfatide metabolism can induce cell apoptosis due to endosome-mediated ceramide generation and the accumulation of cytotoxic levels of sulfatides in lysosomes.


Asunto(s)
Apoptosis/efectos de los fármacos , Endosomas/fisiología , Lisosomas/fisiología , Neuroblastoma/patología , Sulfoglicoesfingolípidos/farmacología , Animales , Línea Celular Tumoral , Femenino , Citometría de Flujo , Etiquetado Corte-Fin in Situ , Espectrometría de Masas , Ratones , Embarazo , Espectrometría de Fluorescencia , Sulfoglicoesfingolípidos/metabolismo
18.
Neurochem Int ; 52(4-5): 709-22, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-17919781

RESUMEN

Activation of protein kinase C (PKC) decreases the activity and cell surface expression of the predominant forebrain glutamate transporter, GLT-1. In the present study, C6 glioma were used as a model system to define the mechanisms that contribute to this decrease in cell surface expression and to determine the fate of internalized transporter. As was previously observed, phorbol 12-myristate 13-acetate (PMA) caused a decrease in biotinylated GLT-1. This effect was blocked by sucrose or by co-expression with a dominant-negative variant of dynamin 1, and it was attenuated by co-expression with a dominant-negative variant of the clathrin heavy chain. Depletion of cholesterol with methyl-beta-cyclodextrin, co-expression with a dominant-negative caveolin-1 mutant (Cav1/S80E), co-expression with dominant-negative variants of Eps15 (epidermal-growth-factor receptor pathway substrate clone 15), or co-expression with dominant-negative Arf6 (T27N) had no effect on the PMA-induced loss of biotinylated GLT-1. Long-term treatment with PMA caused a time-dependent loss of biotinylated GLT-1 and decreased the levels of GLT-1 protein. Inhibitors of lysosomal degradation (chloroquine or ammonium chloride) or co-expression with a dominant-negative variant of a small GTPase implicated in trafficking to lysosomes (Rab7) prevented the PMA-induced decrease in protein and caused an intracellular accumulation of GLT-1. These results suggest that the PKC-induced redistribution of GLT-1 is dependent upon clathrin-mediated endocytosis. These studies identify a novel mechanism by which the levels of GLT-1 could be rapidly down-regulated via lysosomal degradation. The possibility that this mechanism may contribute to the loss of GLT-1 observed after acute insults to the CNS is discussed.


Asunto(s)
Transportador 2 de Aminoácidos Excitadores/metabolismo , Acetato de Tetradecanoilforbol/farmacología , Factor 6 de Ribosilación del ADP , Factores de Ribosilacion-ADP/genética , Factores de Ribosilacion-ADP/metabolismo , Biotina/metabolismo , Western Blotting , Línea Celular Tumoral , Membrana Celular/metabolismo , Colesterol/metabolismo , Clatrina/metabolismo , ADN Complementario/biosíntesis , ADN Complementario/genética , Dinaminas/metabolismo , Humanos , Lisosomas/efectos de los fármacos , Lisosomas/fisiología , Proteínas de la Membrana/metabolismo , Proteína Quinasa C/metabolismo , Sacarosa/farmacología , Transfección , Proteínas de Unión al GTP rab/biosíntesis , Proteínas de Unión al GTP rab/genética , Proteínas de Unión a GTP rab7
19.
J Cell Sci ; 120(Pt 2): 353-65, 2007 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-17215451

RESUMEN

The brain-associated LAMP-like molecule (BAD-LAMP) is a new member of the family of lysosome associated membrane proteins (LAMPs). In contrast to other LAMPs, which show a widespread expression, BAD-LAMP expression in mice is confined to the postnatal brain and therein to neuronal subpopulations in layers II/III and V of the neocortex. Onset of expression strictly parallels cortical synaptogenesis. In cortical neurons, the protein is found in defined clustered vesicles, which accumulate along neurites where it localizes with phosphorylated epitopes of neurofilament H. In primary neurons, BAD-LAMP is endocytosed, but is not found in classical lysosomal/endosomal compartments. Modification of BAD-LAMP by addition of GFP revealed a cryptic lysosomal retention motif, suggesting that the cytoplasmic tail of BAD-LAMP is actively interacting with, or modified by, molecules that promote its sorting away from lysosomes. Analysis of BAD-LAMP endocytosis in transfected HeLa cells provided evidence that the protein recycles to the plasma membrane through a dynamin/AP2-dependent mechanism. Thus, BAD-LAMP is an unconventional LAMP-like molecule and defines a new endocytic compartment in specific subtypes of cortical projection neurons. The striking correlation between the appearance of BAD-LAMP and cortical synatogenesis points towards a physiological role of this vesicular determinant for neuronal function.


Asunto(s)
Proteínas de Membrana de los Lisosomas/metabolismo , Lisosomas/fisiología , Neuronas/metabolismo , Secuencias de Aminoácidos , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Encéfalo/citología , Encéfalo/metabolismo , Membrana Celular/metabolismo , Corteza Cerebral/citología , Corteza Cerebral/metabolismo , Secuencia Conservada , Cisteína/química , Disulfuros/química , Dinaminas/metabolismo , Endocitosis/fisiología , Proteínas Fluorescentes Verdes/metabolismo , Células HeLa , Humanos , Inmunohistoquímica , Proteínas de Membrana de los Lisosomas/química , Ratones , Ratones Endogámicos , Microscopía Confocal , Datos de Secuencia Molecular , Peso Molecular , Neuronas/citología , Estructura Terciaria de Proteína , ARN Mensajero/metabolismo , Homología de Secuencia de Aminoácido , Distribución Tisular , Transfección
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA